Introduction: Meningioma is the most common primary brain tumour and is classified as benign (WHO I, ~80%), a-typical (WHO II, ~15-20%) and anaplastic/malignant (WHO III, ~1-3%). The 3-year recurrence rate in WHO I meningioma is about 50% and it is much greater in WHO II and III. Recent studies showed that cyclin D1 and E1 positively correlated with meningioma grade and higher rates of recurrence, suggesting these proteins as potential prognostic markers for meningioma.
contribute to control tumour progression, characterised by higher expression of cyclin D1-D2 and E1. In addition, WHO III cells and tissues are characterised by a considerable overexpression of the transcription factor GATA4, which is involved in miR-15 family regulation. Ongoing studies will address whether these findings may represent potential diagnostic and/or prognostic biomarkers by analysing circulating exosomes, to improve the diagnosis and stratification of meningiomas. (*These Authors contributed equally)
